Compare Adaptive Biotechnologies Corp (ADPT) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs MGM Resorts International — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while MGM Resorts International trades at $46.41 (market cap $11.93B). The key difference: MGM Resorts International is far larger — about 3.6× Adaptive Biotechnologies Corp's market cap, and MGM Resorts International pays a 0.03% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MGM | |
|---|---|---|
Market Cap | $3.33B | $11.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $50.69 |
52-Week Low | $10.24 | $30.72 |
Enterprise Value | $3.19B | $40.98B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MGM Resorts International (MGM) trades at $46.64, down 0.98% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.49, slightly missing expectations, while Q4 2025 saw a significant beat. Revenue growth has been steady, reaching $17.54B in 2025, though net income margins have compressed to 1.03%. Recent news highlights a potential acquisition offer from Barry Diller at $48.30 per share, under investigation by BFA Law.
The outlook for MGM is cautiously optimistic, supported by analyst consensus leaning Buy (48.64%) and a price target of $45.45. Opportunities include strategic partnerships and digital expansion via BetMGM, but risks persist from high debt levels, regulatory scrutiny, and volatile earnings performance. Investors should weigh the acquisition premium against fundamental valuation metrics like a high P/E of 64.22.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
